Aromatase inhibitor-induced loss of grip strength is body mass index dependent: Hypothesis-generating findings for its pathogenesis

Annals of Oncology

Volumn 22, Issue 8, 2011, Pages 1763-1769

  Lintermans, A ^a   van Calster, B ^b   van Hoydonck, M ^b   Pans, S ^b   Verhaeghe, J ^a   Westhovens, R ^b   Henry, N L ^c   Wildiers, H ^b   Paridaens, R ^b   Dieudonne A S ^a   Leunen, K ^a,b   Morales, L ^b   Verschueren, K ^b   Timmerman, D ^a   de Smet, L ^a   Vergote, I ^a   Christiaens, M R ^a,b   Neven, P ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Aromatase inhibitors; Arthralgia; BMI; Breast cancer; IGF I; Magnetic resonance imaging

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; LETROZOLE; TAMOXIFEN; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GRIP STRENGTH; HAND GRIP; HUMAN; JOINT STIFFNESS; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SYNOVIAL FLUID; SYNOVITIS; TREATMENT DURATION;

EID: 79955412123     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq699     Document Type: Article

References (61)

1. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
2. Goss P, Ingle J, Martino S et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 2007; 25: 2006-2011.
3. Coombes R, Hall E, Gibson L et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
4. Coombes R, Kilburn L, Snowdon C et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559-570.
5. Thürlimann B, Keshaviah A, Coates A et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757.
6. Coates A, Keshaviah A, Thürlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
7. Rabaglio M, Aebi S, Castiglione-Gertsch M. Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Lancet Oncol 2007; 8: 940-949.
8. Morales L, Neven P, Paridaens R. Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. Curr Opin Oncol 2005; 17: 559-565.
9. Dunn B, Ryan A. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators. Ann N Y Acad Sci 2009; 1155: 141-161.
10. Donnellan P, Douglas S, Cameron D, Leonard R. Aromatase inhibitors and arthralgia. J Clin Oncol 2001; 19: 2767.
11. Bonneterre J, Thürlimann B, Robertson J et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18: 3748-3757.
12. Buzdar A, Howell A, Cuzick J et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006; 7: 633-643.
13. Nabholtz J, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-3767.
14. Goss P, Ingle J, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
15. Sestak I, Sapunar F, Cuzick J. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 2009; 27: 4961-4965.
16. Morales L, Pans S, Paridaens R et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 2007; 104: 87-91.
17. Burstein H. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007; 16: 223-234.
18. Henry N, Giles J, Stearns V. Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. Oncology (Williston Park) 2008; 22: 1401-1408.
19. Henry N, Giles J, Ang D et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2008; 111: 365-372.
20. Crew K, Greenlee H, Capodice J et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007; 25: 3877-3883.
21. Muslimani A, Spiro T, Chaudhry A et al. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms? Clin Breast Cancer 2009; 9: 34-38.
22. Morales L, Pans S, Verschueren K et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008; 26: 3147-3152.
23. Dizdar O, Ozçakar L, Malas F et al. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 2009; 27: 4955-4960.
24. Henry N, Jacobson J, Banerjee M et al. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Cancer 2010; 116: 4360-4367.
25. Laroche M, Borg S, Lassoued S et al. Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome. J Rheumatol 2007; 34: 2259-2263.
26. Henry N, Pchejetski D, A'Hern R et al. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br J Cancer 2010; 103: 291-296.
27. Crew K, Capodice J, Greenlee H et al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 2010; 28: 1154-1160.
28. Mao J, Bruner D, Stricker C et al. Feasibility trial of electroacupuncture for aromatase inhibitor-related arthralgia in breast cancer survivors. Integr Cancer Ther 2009; 8: 123-129.
29. Sestak I, Cuzick J, Sapunar F et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 2008; 9(9): 866-872.
30. Xepapadakis G, Ntasiou P, Koronarchis D et al. New views on treatment of aromatase inhibitors induced arthralgia. Breast 2010; 19: 249-250.
31. Sestak I, Cuzick J, Sapunar F et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 2008; 9: 866-872.
32. Szoeke C, Cicuttini F, Guthrie J, Dennerstein L. The relationship of reports of aches and joint pains to the menopausal transition: a longitudinal study. Climacteric 2008; 11: 55-62.
33. World Medical Association. Review of the Declaration of Helsinki. JAMA 1997; 227: 925-926.
34. Goodman L. On simultaneous confidence intervals for multinomial proportions. Technometrics 1965; 7: 247-254.
35. Conover W. Practical Nonparametric Statistics. New York: John Wiley and Sons 1980.
36. Schabenberger O. Mixed model influence diagnostics. In Proceedings of the 29th Annual SAS Users Group International Conference. Montreal, Canada: SAS Institute Inc 2004; 1-17.
37. Flores C, Shughrue P, Petersen S, Mokha S. Sex-related differences in the distribution of opioid receptor-like 1 receptor mRNA and colocalization with estrogen receptor mRNA in neurons of the spinal trigeminal nucleus caudalis in the rat. Neuroscience 2003; 118: 769-778.
38. Felson D, Cummings S. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 2005; 52: 2594-2598.
39. Eckersell C, Popper P, Micevych P. Estrogen-induced alteration of mu-opioid receptor immunoreactivity in the medial preoptic nucleus and medial amygdala. J Neurosci 1998; 18: 3967-3976.
40. Blomqvist A. Sex hormones and pain: a new role for brain aromatase? J Comp Neurol 2000; 423: 549-551.
41. Benderly M, Boyko V, Goldbourt U. Relation of body mass index to mortality among men with coronary heart disease. Am J Cardiol 2010; 106: 297-304.
42. de Wit L, van Straten A, van Herten M et al. Depression and body mass index, a u-shaped association. BMC Public Health 2009; 9: 14.
43. Chen Y, Chen T, Yip P et al. Body mass index (BMI) at an early age and the risk of dementia. Arch Gerontol Geriatr 2010; 50 (Suppl 1): S48-S52.
44. Klenk J, Nagel G, Ulmer H et al. Body mass index and mortality: results of a cohort of 184,697 adults in Austria. Eur J Epidemiol 2009; 24: 83-91.
45. Holmes M, Pollak M, Hankinson S. Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002; 11: 862-867.
46. Lukanova A, Söderberg S, Stattin P et al. Nonlinear relationship of insulin-like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of adiposity and plasma insulin concentrations (Sweden). Cancer Causes Control 2002; 13: 509-516.
47. Lukanova A, Lundin E, Zeleniuch-Jacquotte A et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 2004; 150: 161-171.
48. Crowe F, Key T, Allen N et al. A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1-2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Hum Biol 2010; in press.
49. Gram I, Norat T, Rinaldi S et al. Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. Int J Obes (Lond) 2006; 30: 1623-1631.
50. Blackman M, Sorkin J, Münzer T et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 2002; 288: 2282-2292.
51. Lien E, Johannessen D, Aakvaag A, Lønning P. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. J Steroid Biochem Mol Biol 1992; 41: 541-543.
52. Janssen Y, Helmerhorst F, Frölich M, Roelfsema F. A switch from oral (2 mg/day) to transdermal (50 microg/day) 17beta-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency. J Clin Endocrinol Metab 2000; 85: 464-467.
53. Decensi A, Bonanni B, Guerrieri-Gonzaga A et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998; 90: 1461-1467.
54. Decensi A, Robertson C, Viale G et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003; 95: 779-790.
55. Kuhn M, Wang X, Payne W et al. Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in dupuytren's affected palmar fascia. J Surg Res 2002; 103: 146-152.
56. Bajetta E, Ferrari L, Celio L et al. The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels. J Steroid Biochem Mol Biol 1997; 63: 261-267.
57. Ferrari L, Martinetti A, Zilembo N et al. Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. J Steroid Biochem Mol Biol 2002; 80: 411-418.
58. Cigler T, Tu D, Yaffe M et al. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat 2010; 120: 427-435.
59. Frost V, Helle S, Lønning P et al. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J Clin Endocrinol Metab 1996; 81: 2216-2221.
60. Harper-Wynne C, Sacks N, Shenton K et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 2002; 20: 1026-1035.
61. Lombardi G, Minuto F, Tamburrano G et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest 2009; 32: 202-209.